Institute of Cancer Research | November 2020 | What are the biggest issues in drug discovery and development?
A panel of academic and industry experts have called on the NHS to pay less for drugs used to treat cancer. The summit held last summer by the Institute of Cancer Research (ICR) brought leading organisations from across the academic, charity, pharmaceutical and medical sectors.
The Summer Summit brought together experts from 16 leading academic institutions, charities, stakeholder groups and pharmaceutical companies and calls for a ‘variable pricing’ model based on the benefits they deliver to patients. The peer organistaions that participated in the summit, reached consensus and they identify several measures that will improve the current system of developing drugs, these are some of the solutions proposed to some of the biggest issues in drug discovery and development.
- Increasing incentives to discover and develop innovative treatments
- Enabling companies to work together more easily
- Flexible pricing for new medicines
- Improving the creation and use of biomarker tests
- New indicators of effectiveness to speed up clinical trials
The stakeholders at the summit also developed a nine point plan looking at practical recommendations to improve access to new cancer treatment.
The fuull blog post is available from The Institute of Cancer Research
The list of consensus statements is available from The Institute of Cancer Research
See also:
BMJ NHS should vary price it pays for cancer drugs to improve access, say experts